OBJECTIVE: To determine the correlation between methylene blue use and toxic metabolic encephalopathy in patients undergoing surgery for primary hyperparathyroidism. STUDY DESIGN AND SETTING: A retrospective study of 193 patients was performed to collect demographic, perioperative, and postoperative data. Patients were divided into two groups: Group A (postoperative neurological sequelae) and Group B (no neurological sequelae). All data points were compared between the groups. RESULTS: Twelve of 193 patients were placed in Group A; 181 patients were placed in Group B. Ten patients in Group A were female, and 10 patients were older than 60 years. Of the patients in Group A, 100% were taking a serotonin reuptake inhibitor (SRI). In Group B, 8.8% of patients were taking an SRI. CONCLUSION: All the patients who experienced transient neurological events were taking an SRI. A correlation can be made between methylene blue infusion and SRI usage. SIGNIFICANCE: Patients taking SRIs may represent a high-risk group for postoperative neurological events when methylene blue is utilized.
OBJECTIVE: To determine the correlation between methylene blue use and toxic metabolic encephalopathy in patients undergoing surgery for primary hyperparathyroidism. STUDY DESIGN AND SETTING: A retrospective study of 193 patients was performed to collect demographic, perioperative, and postoperative data. Patients were divided into two groups: Group A (postoperative neurological sequelae) and Group B (no neurological sequelae). All data points were compared between the groups. RESULTS: Twelve of 193 patients were placed in Group A; 181 patients were placed in Group B. Ten patients in Group A were female, and 10 patients were older than 60 years. Of the patients in Group A, 100% were taking a serotonin reuptake inhibitor (SRI). In Group B, 8.8% of patients were taking an SRI. CONCLUSION: All the patients who experienced transient neurological events were taking an SRI. A correlation can be made between methylene blue infusion and SRI usage. SIGNIFICANCE: Patients taking SRIs may represent a high-risk group for postoperative neurological events when methylene blue is utilized.
Authors: Q R J G Tummers; F P R Verbeek; B E Schaafsma; M C Boonstra; J R van der Vorst; G-J Liefers; C J H van de Velde; J V Frangioni; A L Vahrmeijer Journal: Eur J Surg Oncol Date: 2014-02-22 Impact factor: 4.424
Authors: Murat Oz; Dmytro Isaev; Dietrich E Lorke; Muhammed Hasan; Georg Petroianu; Toni S Shippenberg Journal: Br J Pharmacol Date: 2012-05 Impact factor: 8.739
Authors: Quirijn R J G Tummers; Abbey Schepers; Jaap F Hamming; J Kievit; John V Frangioni; Cornelis J H van de Velde; Alexander L Vahrmeijer Journal: Surgery Date: 2015-05-06 Impact factor: 3.982
Authors: Joost R van der Vorst; Boudewijn E Schaafsma; Floris P R Verbeek; Rutger-Jan Swijnenburg; Quirijn R J G Tummers; Merlijn Hutteman; Jaap F Hamming; Job Kievit; John V Frangioni; Cornelis J H van de Velde; Alexander L Vahrmeijer Journal: Head Neck Date: 2013-10-04 Impact factor: 3.147